Skip to content

Theravance Biopharma TBPH Balance Sheet Statement

FY'25FY'24FY'23FY'22
$167.81M+344%$37.8M-4.4%$39.55M-86.7%$298.17M+231%
$147.55M+192%$50.55M-19.6%$62.88M+115%$29.31M-64.9%
$418.46M+160%$161.07M+20.6%$133.54M-62.2%$353.46M+41.5%
$5.9M-20.5%$7.42M-18.2%$9.07M-23.6%$11.88M-13.0%
$485.57M+37.1%$354.16M-7.3%$382M-37.1%$607.4M+62.1%
$2.57M+14.5%$2.24M+47.1%$1.52M-1.9%$1.55M-49.8%
$38.3M+19.4%$32.09M+29.5%$24.77M-13.7%$28.72M-51.0%
$1K$1K0.0%
-$859.63M+11.0%-$965.52M-6.2%-$909.1M-6.5%-$853.91M+50.5%
$296.72M+69.0%$175.55M-17.6%$213M-51.8%$441.8M+230%
$485.57M+37.1%$354.16M-7.3%$382M-37.1%$607.4M+62.1%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Theravance Biopharma's total assets?
Theravance Biopharma (TBPH) holds $472.3M in total assets, up 37.5% year over year.
How much debt does Theravance Biopharma have?
Theravance Biopharma carries $40.5M in total debt against $290.6M of shareholders' equity, a debt-to-equity ratio of 0.14.
How much cash does Theravance Biopharma have?
Theravance Biopharma holds $288.1M in cash and equivalents.
Can Theravance Biopharma cover its short-term obligations?
Its current ratio is 13.14 — current assets exceed current liabilities.
Where does Theravance Biopharma's balance sheet data come from?
Every line is extracted from Theravance Biopharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.